Association between Mutations in Papain-like Protease (PLpro) of SARS-CoV-2 with COVID-19 Clinical Outcomes

被引:4
|
作者
Tan, Jinlin [1 ]
Wu, Zhilong [2 ]
Hu, Peipei [3 ]
Gan, Lin [4 ]
Wang, Ying [1 ]
Zhang, Dingmei [1 ,5 ]
机构
[1] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou 510080, Peoples R China
[2] Fourth Peoples Hosp Foshan City, Foshan 528000, Peoples R China
[3] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China
[4] Huangpu Dist Ctr Dis Control & Prevent, Guangzhou 510700, Peoples R China
[5] NMPA Key Lab Qual Monitoring & Evaluat Vaccines &, Guangzhou 510080, Peoples R China
来源
PATHOGENS | 2022年 / 11卷 / 09期
关键词
SARS-CoV-2; PLpro; COVID-19; mutation; outcome; INSIGHTS;
D O I
10.3390/pathogens11091008
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Papain-like protease (PLpro) is important for the replication and transcription of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to reveal the PLpro mutations associated with the clinical outcomes of patients. Due to the importance of the S protein in the pathogenicity of SARS-CoV-2, the mutation of the S protein was also analyzed in this study. After downloading the data from the Global Initiative on Sharing Avian Influenza Data (GISAID) database, samples were divided into two groups on the basis of patient status, namely, recovered and dead groups. This study performed a univariate analysis and further explored the association of mutations with patient outcomes through multivariate logistic regression analysis. A total of 138,492 samples were used for analysis. The patients had a mean age of 43.66 +/- 21.56 years, and 51.3% of them were female. Multivariate logistic regression results showed that, compared with men, women had a lower risk of dying from coronavirus disease 2019 (COVID-19) (OR = 0.687, 95%CI: 0.638-0.740). Compared with patients aged 17 years and younger, patients aged 18-64 years (OR = 2.864, 95%CI: 1.982-4.139) and patients over 65 years old (OR = 19.135, 95%CI: 13.280-27.572) had a higher risk of death after infection. Compared with the wild type, P78L (OR = 5.185, 95%CI: 2.763-9.730) and K233Q (OR = 5.154, 95%CI: 1.442-18.416) in PLpro were associated with an increased risk of death. A synergistic interaction existed between age and mutations A146D and P78L. The results of the multivariate logistic regression analysis of the data on vaccinated patients demonstrated that, compared with the wild type, the P78L (OR = 3.376, 95%CI: 2.040-5.585) mutation was associated with an increased risk of death. In conclusion, compared with the wild-type PLpro protein, the P78L and K233Q mutations may increase the risk of death in infected individuals. In addition, a synergistic effect existed between age and P78L and K233Q that increased the risk of death in older patients.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] In silico analysis of SARS-CoV-2 papain-like protease potential inhibitors
    Elseginy, Samia A.
    Anwar, Manal M.
    RSC ADVANCES, 2021, 11 (61) : 38616 - 38631
  • [42] Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors
    Li, Daoqun
    Luan, Junwen
    Zhang, Leiliang
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 538 : 72 - 79
  • [43] Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease Mpro and Papain-like Protease PLpro of SARS-CoV-2
    Santos, Lucianna H.
    Kronenberger, Thales
    Almeida, Renata G.
    Silva, Elany B.
    Rocha, Rafael E. O.
    Oliveira, Joyce C.
    Barreto, Luiza, V
    Skinner, Danielle
    Fajtova, Pavla
    Giardini, Miriam A.
    Woodworth, Brendon
    Bardine, Conner
    Lourenco, Andre Luiz
    Craik, Charles S.
    Poso, Antti
    Podust, Larissa M.
    McKerrow, James H.
    Siqueira-Neto, Jair L.
    O'Donoghue, Anthony J.
    da Silva Junior, Eufranio N.
    Ferreira, Rafaela S.
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2022, 62 (24) : 6553 - 6573
  • [44] Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs
    Kouznetsova, Valentina L.
    Zhang, Aidan
    Tatineni, Mahidhar
    Miller, Mark A.
    Tsigelny, Igor F.
    PEERJ, 2020, 8
  • [45] A cell-based Papain-like Protease (PLpro) activity assay for rapid detection of active SARS-CoV-2 infections and antivirals
    Jimenez-Campos, Anahi G.
    Maestas, Lucas I.
    Velappan, Nileena
    Beck, Brian
    Ye, Chunyan
    Wernsing, Keith
    Mata-Solis, Yaniksa
    Bruno, William J.
    Bussmann, Silas C.
    Bradfute, Steven
    Baca, Justin T.
    Rininsland, Frauke H.
    PLOS ONE, 2024, 19 (12):
  • [46] Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors
    Garland, Olivia
    Ton, Anh-Tien
    Moradi, Shoeib
    Smith, Jason R.
    Kovacic, Suzana
    Ng, Kurtis
    Pandey, Mohit
    Ban, Fuqiang
    Lee, Jaeyong
    Vuckovic, Marija
    Worrall, Liam J.
    Young, Robert N.
    Pantophlet, Ralph
    Strynadka, Natalie C. J.
    Cherkasov, Artem
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2023, 63 (07) : 2158 - 2169
  • [47] Inhibitory effects of senkyuchachosan on SARS-CoV-2 papain-like protease activity in vitro
    Yuka Kiba
    Takashi Tanikawa
    Tsuyoshi Hayashi
    Takami Yokogawa
    Aiko Sano
    Ryuichiro Suzuki
    Masashi Kitamura
    Journal of Natural Medicines, 2024, 78 : 784 - 791
  • [48] Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
    Brian C. Sanders
    Suman Pokhrel
    Audrey D. Labbe
    Irimpan I. Mathews
    Connor J. Cooper
    Russell B. Davidson
    Gwyndalyn Phillips
    Kevin L. Weiss
    Qiu Zhang
    Hugh O’Neill
    Manat Kaur
    Jurgen G. Schmidt
    Walter Reichard
    Surekha Surendranathan
    Jyothi Parvathareddy
    Lexi Phillips
    Christopher Rainville
    David E. Sterner
    Desigan Kumaran
    Babak Andi
    Gyorgy Babnigg
    Nigel W. Moriarty
    Paul D. Adams
    Andrzej Joachimiak
    Brett L. Hurst
    Suresh Kumar
    Tauseef R. Butt
    Colleen B. Jonsson
    Lori Ferrins
    Soichi Wakatsuki
    Stephanie Galanie
    Martha S. Head
    Jerry M. Parks
    Nature Communications, 14
  • [49] Mercapto-pyrimidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication
    Bajaj, Teena
    Wehri, Eddie
    Suryawanshi, Rahul K.
    King, Elizabeth
    Pardeshi, Kundan Singh
    Behrouzi, Kamyar
    Khodabakhshi, Zahra
    Schulze-Gahmen, Ursula
    Kumar, G. Renuka
    Mofrad, Mohammad R. K.
    Nomura, Daniel K.
    Ott, Melanie
    Schaletzky, Julia
    Murthy, Niren
    RSC ADVANCES, 2023, 13 (26) : 17667 - 17677
  • [50] Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19 (vol 15, 10169, 2024)
    Lu, Yongzhi
    Yang, Qi
    Ran, Ting
    Zhang, Guihua
    Li, Wenqi
    Zhou, Peiqi
    Tang, Jielin
    Dai, Minxian
    Zhong, Jinpeng
    Chen, Hua
    He, Pan
    Zhou, Anqi
    Xue, Bao
    Chen, Jiayi
    Zhang, Jiyun
    Yang, Sidi
    Wu, Kunzhong
    Wu, Xinyu
    Tang, Miru
    Zhang, Wei K.
    Guo, Deyin
    Chen, Xinwen
    Chen, Hongming
    Shang, Jinsai
    NATURE COMMUNICATIONS, 2025, 16 (01)